Benzinga | May 10, 2021 06:35AM EDT

Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB in Non-Human Primates

* The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome.

* Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-FHAB over recombinant human IL-12, with a half-life around 40 hours in NHP.

* A significant increase in Interferon-?, a key pleiotropic cytokine associated with anti-tumor mechanisms, was observed following dosing with IL12-FHAB.